Analyst consensus rating

MiNK Therapeutics Analyst Rating: Strong Buy

Direct answer

MiNK Therapeutics's consensus rating is Strong Buy.

2 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $44.00.
Forecast evidence checked November 18, 2026.

Get free MiNK Therapeutics email updates.

Bullstory sends one daily email when new analysis or important company news is available.

Verified data

Current price
$9.29
Average price target
$44.00
High price target
$50.00
Low price target
$38.00
Low target gap
+309.3%
Target upside
+373.9%
High target gap
+438.5%
Target range width
129.2%
Consensus rating
Strong Buy
Analysts
2
Evidence date
November 18, 2026
Valid through
November 25, 2026

Read the frequently asked questions.

What is the analyst consensus rating for MiNK Therapeutics?

MiNK Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $44.00.

How far are MiNK Therapeutics's low and high targets from the recorded price?

The low target implies +309.3%, while the high target implies +438.5%.

How many analysts are included in MiNK Therapeutics's consensus?

The verified consensus includes 2 analysts.

How is MiNK Therapeutics's target upside or downside calculated?

The average target of $44.00 is divided by the recorded price of $9.29, then one is subtracted to produce +373.9%. This does not guarantee a future return.

When was MiNK Therapeutics's analyst forecast verified?

The data was verified on 2026-11-18. The dataset is valid through 2026-11-25.